Luye Pharma Group (HK:2186) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Luye Pharma Group has announced the inclusion of several innovative drugs, including Ruoxinlin and Baituowei, in China’s 2024 National Reimbursement Drug List. This development is expected to enhance patient access and accelerate commercialization, potentially boosting financial returns for the company. The inclusion marks a significant milestone for Luye’s proprietary antidepressant, Ruoxinlin, as a breakthrough ‘Made-in-China’ drug.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
